Drying, Durability, and Disease Control: Evolving Metrics of Anti-VEGF Success in Retinal Diseases

Ehsan Rahimy, MD; David G. Miller, MD, Esther Kim, MD, discusses how achieving retinal drying through anti-VEGF therapies remains a critical marker of treatment success in retinal diseases like AMD and DME, while highlighting the benefits of newer agents like aflibercept 8mg and faricimab for providing better durability and sustained disease control with reduced treatment burden.